Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 01, 2026
DataAggregated Company Financials
Companies63
  • 7D9.4%
  • 3M1.6%
  • 1Y17.1%
  • YTD-12.5%

The Life Sciences industry is up 9.4% in the last week, with Thermo Fisher Scientific up 10%. In the last 12 months, the industry was up 17%. Looking forward, earnings are forecast to grow by 18% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 02 Jun 2026US$595.4bUS$150.6bUS$13.8b37.9x43.3x4x
Thu, 30 Apr 2026US$543.0bUS$149.0bUS$14.4b30.8x37.8x3.6x
Sat, 28 Mar 2026US$551.6bUS$147.8bUS$14.0b34.8x39.3x3.7x
Mon, 23 Feb 2026US$592.1bUS$147.7bUS$13.8b33.8x42.8x4x
Wed, 21 Jan 2026US$693.5bUS$145.8bUS$12.4b36x56.1x4.8x
Fri, 19 Dec 2025US$645.6bUS$145.8bUS$12.5b34.5x51.7x4.4x
Sun, 16 Nov 2025US$649.0bUS$145.7bUS$12.2b34.5x53.2x4.5x
Tue, 14 Oct 2025US$609.0bUS$144.3bUS$14.6b32.1x41.9x4.2x
Thu, 11 Sep 2025US$571.6bUS$144.3bUS$14.6b28.8x39.3x4x
Sat, 09 Aug 2025US$546.8bUS$144.1bUS$13.2b28.5x41.3x3.8x
Mon, 07 Jul 2025US$548.4bUS$142.9bUS$9.1b36.4x60.1x3.8x
Wed, 04 Jun 2025US$501.7bUS$142.9bUS$9.2b34.3x54.7x3.5x
Fri, 02 May 2025US$524.8bUS$142.4bUS$10.0b37.4x52.6x3.7x
Sun, 30 Mar 2025US$575.3bUS$142.5bUS$10.0b37.7x57.8x4x
Tue, 25 Feb 2025US$616.0bUS$143.3bUS$9.7b38.7x63.4x4.3x
Thu, 23 Jan 2025US$702.1bUS$142.4bUS$10.2b44.8x68.8x4.9x
Sat, 21 Dec 2024US$643.3bUS$142.4bUS$10.2b44.3x62.9x4.5x
Mon, 18 Nov 2024US$638.7bUS$142.4bUS$10.4b41.8x61.6x4.5x
Wed, 16 Oct 2024US$736.4bUS$141.8bUS$8.5b37.3x86.7x5.2x
Fri, 13 Sep 2024US$738.4bUS$141.8bUS$8.5b37.7x86.9x5.2x
Sun, 11 Aug 2024US$727.5bUS$141.5bUS$8.5b38.2x85.8x5.1x
Tue, 09 Jul 2024US$664.6bUS$141.3bUS$12.2b38.8x54.6x4.7x
Thu, 06 Jun 2024US$705.0bUS$141.3bUS$12.4b39.9x56.7x5x
Sat, 04 May 2024US$708.1bUS$141.7bUS$12.5b38.9x56.6x5x
Mon, 01 Apr 2024US$744.3bUS$142.0bUS$12.8b44x58.2x5.2x
Wed, 28 Feb 2024US$728.5bUS$142.2bUS$12.8b44.1x57.1x5.1x
Fri, 26 Jan 2024US$686.7bUS$153.8bUS$14.2b35.1x48.5x4.5x
Sun, 24 Dec 2023US$698.9bUS$153.8bUS$14.2b37.5x49.1x4.5x
Tue, 21 Nov 2023US$610.6bUS$153.9bUS$13.9b33.5x43.9x4x
Thu, 19 Oct 2023US$612.3bUS$154.6bUS$11.2b31.8x54.7x4x
Sat, 16 Sep 2023US$692.7bUS$154.6bUS$11.2b33.3x61.8x4.5x
Mon, 14 Aug 2023US$725.3bUS$154.7bUS$11.5b32x63.1x4.7x
Wed, 12 Jul 2023US$695.5bUS$152.4bUS$12.5b29.7x55.6x4.6x
Fri, 09 Jun 2023US$680.8bUS$152.4bUS$12.5b29.1x54.5x4.5x
Price to Earnings Ratio

54.5x


Total Market Cap: US$680.8bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.3x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.58%
Healthcare0.32%
Life Sciences9.39%
Clinical Research and Equipment9.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$494.0410.2%
+US$17.0b		24.6%PE26.8x
A Agilent TechnologiesUS$135.9818.3%
+US$5.9b		22.4%PE27.1x
DHR DanaherUS$179.874.6%
+US$5.6b		-4.9%PE34.6x
WAT WatersUS$378.1610.5%
+US$3.5b		10.0%PE82.6x
IQV IQVIA HoldingsUS$186.8211.3%
+US$3.2b		34.3%PE22.5x

Latest News

WAT
US$378.16
Waters
7D
10.5%
1Y
10.0%
WST
US$316.30
West Pharmaceutical Services
7D
-0.04%
1Y
51.1%
BRKR
US$58.44
Bruker
7D
27.9%
1Y
59.1%
DHR
US$179.87
Danaher
7D
4.6%
1Y
-4.9%
OABI
US$2.61
OmniAb
7D
-1.5%
1Y
85.1%
Narrative Update • Jun 01

OABI: 2026 Revenue Guidance Will Shape Long Term Upside Potential

Analysts have nudged their price target on OmniAb slightly higher to $7.33, reflecting updated assumptions around the company’s discount rate, long term revenue growth, profit margin, and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, projecting revenue in a range of $25 million to $30 million.
SHC
US$15.54
Sotera Health
7D
-0.8%
1Y
27.5%
ILMN
US$164.40
Illumina
7D
13.8%
1Y
102.7%
Narrative Update • Jun 01

ILMN: Clinical Momentum And Softer Competition Will Shape A Balanced Outlook

Analysts have lifted the fair value estimate for Illumina from $156.51 to $175.00, citing Street research that points to building clinical momentum, easing competitive concerns, and a series of higher price targets from several firms. Analyst Commentary Recent Street research on Illumina has tilted more constructive, with several bullish analysts pointing to improving clinical traction and a less intense competitive backdrop as key supports for the stock.
IQV
US$186.82
IQVIA Holdings
7D
11.3%
1Y
34.3%
Narrative Update • May 31

IQV: Future Returns Will Depend On AI Trial Expansion And Execution Risk Balancing

Narrative Update on IQVIA Holdings The analyst price target for IQVIA Holdings has moved from $186.12 to $195.00, reflecting updated assumptions on discount rate, profit margin, and P/E, alongside recent research in which several firms reiterated constructive views on clinical trial activity, AI related cost savings, and the stock's valuation. Analyst Commentary Recent Street research on IQVIA Holdings has been mixed, with some bullish rating changes and initiations sitting alongside lower price targets from more cautious voices.
ICLR
US$138.03
ICON
7D
18.2%
1Y
7.1%
RPID
US$1.97
Rapid Micro Biosystems
7D
-3.9%
1Y
-42.9%
New Narrative • May 30

Automation And Advanced Biomanufacturing Adoption Will Drive Long Term Value For This QC Leader

Catalysts About Rapid Micro Biosystems Rapid Micro Biosystems provides automated microbial quality control systems and consumables for biopharma and related regulated industries. What are the underlying business or industry changes driving this perspective?
TMO
US$494.04
Thermo Fisher Scientific
7D
10.2%
1Y
24.6%
MLAB
US$105.26
Mesa Laboratories
7D
-3.1%
1Y
7.5%
CDT
US$0.90
CDT Equity
7D
-14.8%
1Y
-99.9%
A
US$135.98
Agilent Technologies
7D
18.3%
1Y
22.4%
LFCR
US$4.85
Lifecore Biomedical
7D
-1.6%
1Y
-29.4%
Narrative Update • May 28

LFCR: CDMO Site Transfers And 2028 Ramps Will Support Future Upside

Narrative Update: Lifecore Biomedical Analysts have adjusted their average price target for Lifecore Biomedical toward $5 to $5.50, reflecting mixed recent research in which one firm lifted its target by $0.50 while another reduced its target by $3.50. The firms cited the timing of commercial ramps and a slightly later potential breakout year as key drivers.
CSBR
US$5.84
Champions Oncology
7D
-2.8%
1Y
2.1%